No evidence of intrauterine sensitization against inhalant allergens
To the Editor:
Allergen-specific IgE can be detected in cord blood (CB), but the origin and relevance of this finding is controversial. We previously reported that specific IgE in CB against inhalant allergens mainly seemed to be the result of transfer of maternal IgE to the fetus, 1 whereas others suggested that such IgE is of fetal origin, [2] [3] [4] [5] [6] thus representing intrauterine sensitization. This distinction is important: intrauterine sensitization could be targeted by prenatal intervention and would suggest CB specific IgE as a relevant disease marker in the newborn, whereas maternally transferred IgE, either as a sampling artifact or due to transplacental transfer, would have no independent value as a disease marker and no long-term consequences for allergy in the offspring.
Here, we aimed to test the hypothesis that specific IgE against inhalant allergens in CB is of maternal origin. We hypothesized that applying strict sampling procedures and including unselected women with low levels of IgE would result in limited, if any, specific IgE in CB.
Women with singleton pregnancies were invited to participate in the study, as previously described. 7 The investigation conformed to the Declaration of Helsinki and was approved by the Scientific Ethics Committee and the Danish Data Surveillance Authority.
Blood was taken from the umbilical vein by needle puncture performed by a single investigator. Samples were available for 260 maternal blood (MB)-CB pairs. IgE antibody levels were determined using the ImmunoCAP assay (Thermo Fisher Scientific, Uppsala, Sweden). MB and CB were analyzed for levels of specific IgE against common inhalant and food allergens (lower detection limit, 0.1 kUa/L) and for total IgE (lower detection limit, 0.1 kU/L using a combination of the standard and low-level total IgE assays). IgA levels in CB samples were analyzed by ELISA (detection limit, 0.1 mg/L). Further information on methodology can be found in this article's Online Repository at www.jacionline.org.
An elevated IgA level in CB (>50 mg/L) was considered indicative of contamination with MB. 1, 8 This was found in only 3 (1%) of the CB samples compared with 21 samples (9%) in our previous study. 8 High levels of specific IgE in MB (sum of specific IgE >100 kUa/L) were found in 4 samples (2%) compared with 12 samples (5%) in our previous study 1 (Table I) . Correspondingly, specific IgE against inhalant allergens (> _0.1 kUa/L) was found in only 2 CB samples (<1%) compared with 22 (9%) in our previous study 1 (Table I and Fig 1) . In Fig 1, the relationship between specific IgE against inhalant allergens in CB and MB is depicted. We have included prediction lines for the level of specific IgE in CB in relation to the level in MB, stratified by level of CB IgA, based on results from our previous study. 1 As predicted, specific IgE against inhalant allergens in CB was present only when either the level of CB IgA was very high or the corresponding maternal sample had highly elevated levels of specific IgE. For the 2 CB samples with specific IgE against inhalant allergens, corresponding IgE against the same allergen was found in the maternal sample for 2 out of 3 allergens (see Fig E1 in In accordance with our hypothesis, we found a very low frequency of specific IgE against inhalant allergens in CB after applying strict sampling procedures and predominately including women with low levels of specific IgE. On the basis of the present study and our previous studies, 1, 8 we hypothesize 2 different mechanisms of transfer of IgE from MB to CB. First, there seems to be an IgA-associated mechanism. IgA does not pass the placental barrier, and a high level of IgA in CB is expected to reflect contamination with MB. Our current results support such (preventable) mechanism taking place during CB sampling, because strict sampling procedures performed by a single researcher, rather than sampling done by many different midwifes, resulted in just 1% of the samples with IgA levels in the range interpreted as contamination (>50 mg/L), compared with 9% in our previous study. 8 Second, we suggest a mechanism of transfer of IgE from the mother to the fetus that is not IgA-associated and not related to CB sampling procedures. This is based on our previous findings that very high maternal levels of IgE (specific or total) always resulted in detectable IgE levels in CB independent of CB IgA 1, 8 and such mechanism is further supported by the current study in which we similarly observed that total IgE in CB always was detectable when the mother had very high levels of total IgE (>125 kU/L). Combining the results from our 2 studies, we find that IgE in CB was detectable in all 84 samples with a corresponding maternal level of more than 145 kU/L (see Fig E2) . Such consistent relationship seems more compatible with maternofetal transfer than a biological mechanism of fetal IgE production. The possibility of such mechanism is further supported by a recent study demonstrating that transplacental transport of IgE can occur with IgE bound to an IgG-anti-IgE immune-complex. 9 Our results contrast with those of other studies claiming that specific IgE in CB is of fetal origin.
2-6 Pfefferle et al 6 found detectable specific IgE levels against inhalant allergens in 11% of CB samples without correlation to the presence of such IgE in MB. Limitations to that study include the following: IgA was measured only in a subset of samples, and a much higher level of IgA was used as indicator of contamination. Another possible explanation for the discrepancy between studies is the use of different methods for IgE measurement (ImmunoCAP, Thermo Fisher Scientific, Uppsala, Sweden vs Allergy Screen, Mediwiss Analytic, Moers, Germany).
We found 3 CB samples with elevated specific IgE against milk and no sign of transfer from the mother. This is in contrast to our previous study in which no such IgE was found in CB.
1 CB IgE against milk could be due to cross-reactivity with fetal proteins, but we cannot rule out the possibility of (rare) fetal synthesis of IgE against food allergens.
CB IgE is currently used as a surrogate marker of later sensitization and it is therefore crucial to be able to discriminate between IgE transferred from the mother and synthesis by the fetus. Our data strongly suggest that specific IgE against inhalant allergens in CB is of maternal origin. Findings of such IgE in previous and future studies should therefore be interpreted with caution.
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To clarify the mechanisms underlying Ascl2-induced T FH cell differentiation, we first examined the requirement of transcriptional activity of Ascl2 for the expression of CXCR5, one of the T FH cell markers.
1,2 Consistent with a previous report, 3 overexpression of Ascl2 upregulated CXCR5 expression on CD4
1 T cells, especially in T FH cell-inducing conditions (Fig 1, A, and see the Methods section in this article's Online Repository at www. jacionline.org). In contrast, E127G Ascl2, which is incapable of binding to DNA, did not induce CXCR5 expression (Fig 1, A) , suggesting that DNA binding of Ascl2 is essential for CXCR5 induction.
We next performed the comprehensive survey of genes regulated by Ascl2 by using chromatin immunoprecipitation sequencing (ChIP-seq) analysis. Consistent with a previous report, 3 Ascl2 bound to a promoter region of Cxcr5 (Fig 1, B) . In addition, among T FH cell-related molecules, Ascl2 bound to a promoter region of Nfkbid (coding for inhibitory k BNS [IkBNS] ; Fig 1, B) , which plays important roles in T-dependent antibody responses. 4 On the other hand, Ascl2 did not bind to promoter regions of other T FH cell-related genes, including Irf4, Batf, Maf, and Nfkb1 (Fig 1, B) . Indeed, expression of IkBNS was significantly upregulated in Ascl2-transduced CD4
1 T cells (Fig 1, C) . Furthermore, IkBNS was expressed at higher levels in programmed death 1 (PD-1)
cells (non-T FH cells) or naive CD4
1 T cells (Fig 1, D) , which is consistent with RNA sequencing data deposited by Weinstein et al 5 showing that T FH cells express higher levels of IkBNS mRNA than naive CD4
1

T cells in human subjects. Taken together, these results suggest that IkBNS is upregulated in CD4
1 T cells by Ascl2 and could be involved in the differentiation of T FH cells.
To
clarify the roles of IkBNS in the differentiation of T FH cells, we next examined the ability of IkBNS-deficient (IkBNS
1 T cells to differentiate into T FH cells on antigen stimulation by using an adoptive transfer system. Because IkBNS has been shown to play important roles in B cells, 6 after naive CD4
T cells from ovalbumin (OVA)-specific T-cell receptor (TCR) transgenic mice (OT-II mice) and OT-II$IkBNS
2/2 mice were injected intravenously to T cell-deficient TCRbd double-deficient (TCRbd 2/2 ) mice, the mice were immunized with NP-OVA, and the development of T FH cells in the spleen was analyzed by means of flow cytometry. Although no significant difference was observed in the number of total CD4 1 T cells between these 2 groups (data not shown), the frequencies of PD-1 1 CXCR5
1 T FH cells (Fig 2, A) and CD4 1 T cells expressing both CXCR5 and Bcl6 (Fig 2, B) , a master regulator of T FH cells, 1,2 were significantly decreased in mice transplanted with OT-II$IkBNS 2/2 CD4 1 T cells compared with those with control OT-II CD4 1 T cells. NP-specific IgG 1 was also significantly decreased in mice transplanted with OT-II$IkBNS 2/2 CD4 1 T cells compared with those with OT-II$CD4 1 T cells (Fig 2, C) , suggesting that IkBNS expressed in CD4 1 T cells plays an important role in humoral immune responses. Consistently, mice transplanted with another type of OVA-specific DO11.10 CD4 1 T cells with silenced IkBNS exhibited reduced T FH cell numbers (see Fig E1, A, in this article's Online Repository at www. jacionline.org) and impaired germinal center formation (see Fig E1, B) on immunization with OVA.
We also investigated the effect of overexpression of IkBNS on T FH cell differentiation. In this experiment naive CD4
1 T cells from OT-II mice were infected with retroviruses of IkBNS or controls, and the infected cells were injected intravenously into TCRbd /-mice. As shown in Fig 2, D , when these mice were immunized with NP-OVA, the frequency of T FH cells was significantly higher in mice transplanted with IkBNS-expressing CD4
1 T cells than in those transplanted with control CD4
1 T cells, confirming that IkBNS plays a key role in T FH cell differentiation. Mice transplanted with DO11.10 CD4 1 T cells overexpressing IkBNS also increased T FH cell numbers (see Fig E2, A, in this article's
METHODS
Study participants
A total of 756 randomly selected women with singleton pregnancies admitted to the Department of Obstetrics and Gynecology were invited to participate in the study (June 2003 to April 2004) as previously described.
E1
Women with diabetes mellitus, multiple gestations, a previous pregnancy with stillbirth, intrauterine growth restriction, or congenital malformations were not invited to participate. At the antenatal visit at approximately 12 weeks of gestation, 557 of the 756 women gave informed and written consent. The investigation conformed to the principles outlined in the Declaration of Helsinki and was approved by the Scientific Ethics Committee (H-1-2009-106 ) and the Danish Data Surveillance Authority (2015-41-3879) .
Of the 557 women, 116 did not meet the inclusion criteria, and 175 women gave birth when the investigator (M.R.A.) was unavailable, leaving 266 women for inclusion.
Six blood samples were not obtained by needle puncture from the fetal umbilical vein immediately after placental delivery, leaving 260 women and their newborns in the main study.
Sampling of CB and MB
E1 To avoid contamination, sampling of CB was done by a well-trained person; blood was taken from the umbilical vein by needle puncture.
Determination of serum total IgE, specific IgE, and total IgA IgE antibody levels were determined using the ImmunoCAP assay (Thermo Fisher Scientific, Uppsala, Sweden). E2 CB was analyzed for levels of total IgE and specific IgE against a mixture of common inhalant and food allergens (Phadiatop Infant).
E3
Samples positive for Phadiatop Infant (> _0.1 kUa/L) were further analyzed for specific IgE against relevant single allergens from this panel (Dermatophagoides pteronyssinus, cat dander, dog dander, birch, timothy, mugwort, peanut, cow's milk, and hen's egg). The detection limit for total and specific IgE was 0.1 kUa/L. Specific IgE results in CB were doubletested. MB was analyzed similarly for levels of total IgE and specific IgE against the same inhalant and food allergens after screening with Phadiatop and fx5. A screening value of 0.35 kUa/L or more was considered positive. Specific IgE against single allergens in MB was analyzed irrespective of the screening result if such IgE was found in the corresponding CB sample. The lower detection limit was 0.1 kUa/L for allergen-specific IgE and 0.1 kU/L for total IgE (by using a combination of the standard and low-level total IgE assays with lower detection limits of 2.0 and 0.1 kU/L, respectively).
CB samples were analyzed for total IgA by using a sensitive ELISA designed to measure low levels of IgA (detection limit, 0.1 mg/L; analyzed by Phadia AB). A CB level of IgA of more than 50 mg/L was considered indicative of transfer of MB to CB based on results from our previous studies using the same IgA methodology. E4,E5 In these previous studies, it was seen that for CB samples with IgA levels of more than 50 mg/L there was a clear association between CB IgA and IgE, which was not seen at lower levels of IgA. This was further supported by a shift upward in the CB versus maternal IgE regression lines for IgA levels greater than 50 mg/L.
Statistical analysis
We modeled the underlying association between specific IgE and total IgE in CB and MB by linear regression and by assuming an underlying normal distribution. By extracting detection limit for IgA calculated in a previous study we analyzed for the association between specific IgE in CB and MB for each level of CB IgA. Maximum likelihood estimates with asymptotic 95% Wald CIs were calculated, and likelihood ratio tests for hypotheses were performed. All values were transformed on a logarithmic scale.
Analyses were carried out using SAS version 9.3 (SAS Institute, Cary, NC).
RESULTS
The median level of IgA in CB was 10.6 mg/L (range, 0-3065 mg/L). Total IgE in CB was detectable in 73% (N 5 190) of the samples. Any specific IgE in MB was found in 80 samples (31%).
Specific IgE against inhalant allergens (> _0.1kUa/L) was found in 2 CB samples (<1%). One sample had detectable IgE against 2 inhalant allergens (common silver birch and D pteronyssinus), and 1 sample had detectable levels against 1 inhalant allergen (D pteronyssinus). Two CB samples with an intermediary level of IgA (between 50 and 100 mg/L) indicative of some degree of contamination had nondetectable specific IgE levels in CB, which is in accordance with the prediction lines, because the corresponding maternal sample was negative for specific IgE (Fig 1) .
The comparison of single specific IgE against inhalant allergens in CB and MB is shown in Fig E1 for the 2 samples with detectable specific IgE levels in CB. Corresponding IgE against the same allergen was found in maternal blood for 2 out of 3 allergens. The black line represents the detection limit of specific IgE in CB (0.1 kUa/L). Allergens: d1, D pteronyssinus; e1, Cat epithelium and dander; e5, dog dander; g6, timothy grass; t3, common silver birch; w6, mugwort; f1, egg white; f2, milk; f3, fish (cod). A, Present study. B, Previous study for comparison. E5 The red line illustrates that, in both studies, all samples with maternal IgE above 145 IU/mL resulted in detectable levels in CB. Scales are log transformed.
